S. Black

发表

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

Transcriptional Regulation during p21 WAF1/CIP1 -induced Apoptosis in Human Ovarian Cancer Cells*

Luquan Wang, T. Mcclanahan, Tong-Yuan Yang, 2002, The Journal of Biological Chemistry.

RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis

J. Lachowicz, A. Mirza, Suxing Liu, 2005, Cancer biology & therapy.

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

W. R. Bishop, E. Maxwell, Marnie McGuirk, 2001, Experimental cell research.

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Brian L. Pearlman, M. Buti, P. Kwo, 2017, Gastroenterology.

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)

P. Kirschmeier, Ming Liu, A. Basso, 2007, Anti-cancer drugs.

Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

E. Asante-Appiah, P. Qiu, F. Lahser, 2019, Antimicrobial Agents and Chemotherapy.

Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.

D. Nickle, A. Howe, R. Barnard, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

R. Bowden, E. Barnes, D. Bonsall, 2018, Infection and drug resistance.

Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

A. Howe, P. Jumes, S. Black, 2015, Antimicrobial Agents and Chemotherapy.

Susceptibilities of Genotype 1 a , 1 b , and 3 Hepatitis C Virus Variants to the NS 5 A Inhibitor Elbasvir

A. Howe, P. Jumes, S. Black, 2015 .

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin

J. Howe, A. Howe, J. Long, 2014, Open forum infectious diseases.

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

H. Yoshiji, K. Chayama, Y. Karino, 2016, Journal of Gastroenterology.

Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a

E. Asante-Appiah, Zhuyan Guo, Yuan Hu, 2017, The Journal of Biological Chemistry.

P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325

Qian Huang, Adam T. Gates, M. Rudd, 2015, ChemMedChem.

P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study

P. Harrigan, A. Howe, C. Brumme, 2015 .

HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.

D. Nickle, N. Hayashi, A. Howe, 2016, Antiviral research.

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules*

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000, The Journal of Biological Chemistry.

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

W. R. Bishop, Luquan Wang, Qun Wu, 2002, Oncogene.

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors

Kathleen M. Smith, T. Mcclanahan, P. Kirschmeier, 2006, Cancer biology & therapy.

Chemical shift assignments and secondary structure of the Grb2 SH2 domain by heteronuclear NMR spectroscopy

L. Perkins, M. Senior, P. Kirschmeier, 1996, Journal of biomolecular NMR.

Dissecting Therapeutic Resistance to ERK Inhibition

L. Zawel, S. Fawell, L. Jayaraman, 2016, Molecular Cancer Therapeutics.

Generation of a Chimeric Hepatitis C Replicon Encoding a Genotype-6a NS3 Protease and Assessment of Boceprevir (SCH503034) Sensitivity and Drug-Associated Mutations

J. Howe, Zhuyan Guo, S. Locarnini, 2015, Antiviral therapy.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

P. Kirschmeier, R. Doll, W. Windsor, 2018, Bioorganic & medicinal chemistry letters.

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A

E. Asante-Appiah, F. Lahser, S. Agrawal, 2018, Antimicrobial Agents and Chemotherapy.